Vancouver, BC – Medipure Holdings Inc. has taken the next step to advance its research and development by creating a subsidiary, Medipure LifeSciences India (MLSI) Pvt Ltd. The focus for MLSI is to create a new state-of-the-art R&D platform for drug discovery through to clinical stage, targeting new and unmet therapeutic needs and supporting the Company’s global R&D endeavors. This will be a core facility for Medipure’s medicinal chemistry activities aimed to develop new and novel drug candidates targeting various diseases. This facility will support Medipure’s preclinical and scale-up activities.
India has immense pharma R&D potential, world class institutions, contract research organizations and a vast talent pool of researchers. In the last decades, India has taken steps to create an environment to attract global preclinical studies. It is important to note that clinical trials comply with international standards set by EU, Health Canada and the FDA.
Medipure’s research is focused on the body’s endocannabinoid system, a previously under-explored network of receptors throughout the body that plays a role in many biological and physiological functions. It’s focused on the development of a safe and non-addictive prescription drug line to address chronic pain, anxiety and a variety of other conditions. The drug formulations could be an economical, non-addictive alternative to opioid and benzodiazepine-based prescription drugs that can be highly addictive with life-altering side effects.
For more information, please visit: http://medipurepharmaceuticals.com